Wells Fargo & Company MN Cuts Holdings in Collegium Pharmaceutical, Inc. (COLL)

Wells Fargo & Company MN decreased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 53.8% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 40,118 shares of the specialty pharmaceutical company’s stock after selling 46,658 shares during the period. Wells Fargo & Company MN owned about 0.14% of Collegium Pharmaceutical worth $502,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. American International Group Inc. lifted its stake in Collegium Pharmaceutical by 27.8% in the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after acquiring an additional 2,163 shares in the last quarter. Nationwide Fund Advisors lifted its stake in Collegium Pharmaceutical by 16.4% in the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after acquiring an additional 1,422 shares in the last quarter. Credit Suisse AG increased its position in shares of Collegium Pharmaceutical by 9.4% during the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after purchasing an additional 1,173 shares during the last quarter. UBS Group AG increased its position in shares of Collegium Pharmaceutical by 283.2% during the 1st quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 10,174 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Collegium Pharmaceutical during the 1st quarter worth approximately $151,000. Hedge funds and other institutional investors own 83.96% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Wells Fargo & Company MN Cuts Holdings in Collegium Pharmaceutical, Inc. (COLL)” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/13/wells-fargo-company-mn-cuts-holdings-in-collegium-pharmaceutical-inc-coll.html.

Several research firms have weighed in on COLL. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, November 8th. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $14.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $20.00.

Collegium Pharmaceutical, Inc. (NASDAQ COLL) opened at $14.09 on Monday. Collegium Pharmaceutical, Inc. has a 1 year low of $7.37 and a 1 year high of $18.02.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. The firm had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The business’s quarterly revenue was up 2814.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.13) EPS. analysts anticipate that Collegium Pharmaceutical, Inc. will post -2.63 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply